USANA Health Sciences (NYSE: USNA) reported Q1 EPS of $1.19, $0.12 better than the analyst estimate of $1.07. Revenue for the quarter came in at $292 million versus the consensus estimate of $274.88 million.

Outlook

The Company is updating its consolidated net sales and earnings per share outlook for 2018 as follows:

• Consolidated net sales between $1.13 and $1.17 billion, previously between $1.11 and $1.16 billion; and
• Earnings per share between $4.25 and $4.55, previously between $4.05 and $4.45.

The Company’s outlook reflects:

• A positive impact from more favorable currency exchange rates of approximately $45 million for the full-year;
• An estimated operating margin of between 13% and 14% for the year;
• An effective tax rate of approximately 34% for the year; and
• An annualized diluted share count of approximately 24.3 million.

GUIDANCE:

USANA Health Sciences sees FY2018 EPS of $4.25-$4.55, versus the consensus of $4.40. USANA Health Sciences sees FY2018 revenue of $1.13-1.17 billion, versus the consensus of $1.13 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.